GUIDELINES FOR SYSTEMIC TREATMENT OF PATIENTS WITH ATOPIC DERMATITIS AT THE UNIVERSITY CLINIC FOR DERMATOLOGY IN SKOPJE
Keywords:
atopic dermatitis, systemic therapy, guidelinesAbstract
This Guideline was developed for the needs of the University Clinic (UC) for Dermatology in Skopje and is based on the European Guidelines for the Systemic Therapy of Atopic Dermatitis (AD) from 2020 and 2021 (EuroGuiDerm Guideline). Dermatologists from the UC for Dermatology with extensive experience in pediatric dermatology and treating patients with AD participated in the process. The Guideline was adopted by the Expert Board of the UC for Dermatovenerology in Skopje in February 2025.
This part of the Guideline contains general information about the goals and scope, the health issues covered in the Guideline, the target groups, and a methodology section. The Guideline provides guidelines for identifying patients who should be treated with systemic therapy and recommendations and information for each systemic drug. In addition, the Guideline provides recommendations and information on each systemic drug. The first section describes systemic treatment options, such as conventional immunosuppressive drugs (azathioprine, cyclosporine, glucocorticosteroids, methotrexate, and mycophenolate mofetil), biologic agents (dupilumab, lebrikizumab, nemolizumab, omalizumab, and tralokinumab) and Janus kinase inhibitors (abrocitinib, baricitinib, and upadacitinib).
References
Wollenberg A, Kinberger M, Arents B, et al. European Guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(12):1904-26. doi:10.1111/jdv.18429
Drucker AM, Lam M, Prieto-Merino D, et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update. JAMA Dermatol. 2024 Sep 1;160(9):936-944. doi: 10.1001/jamadermatol.2024.2192. Erratum in: JAMA Dermatol. 2024 Sep 1;160(9):1012. doi: 10.1001/jamadermatol.2024.3600.
Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156(6):659-67. doi:10.1001/jamadermatol.2020.0657
Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clin Exp Dermatol. 2001;26(5):369-75. doi:10.1046/j.1365-2230.2001.00796.x
Taylor AE, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Derm Venereol. 1992;72(2):115-9.
Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33(9):1644-59. doi:10.1111/jdv.15663
Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133(2):429-38. doi:10.1016/j.jaci.2013.06.040
van der Schaft J, van Zuilen AD, Deinum J, Bruijnzeel-Koomen CA, de Bruin-Weller MS. Serum creatinine levels during and after long-term treatment with cyclosporine A in patients with severe atopic dermatitis. Acta Derm Venereol. 2015;95(8):963-7. doi:10.2340/00015555-2100
Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-23. doi:10.1056/NEJMra050541
Richter B, Neises G, Clar C. Glucocorticoid withdrawal schemes in chronic medical disorders. A systematic review. Endocrinol Metab Clin North Am. 2002;31(4):751-78. doi:10.1016/s0889-8529(02)00046-1
Taieb Y, Baum S, Ben Amitai D, Barzilai A, Greenberger S. The use of methotrexate for treating childhood atopic dermatitis: a multicenter retrospective study. J Dermatolog Treat. 2019;30(3):240-4. doi:10.1080/09546634.2018.1465812
Shah N, Alhusayen R, Walsh S, Shear NH. Methotrexate in the treatment of moderate to severe atopic dermatitis: a retrospective study. J Cutan Med Surg. 2018;22(5):484-7. doi:10.1177/1203475418778377
Phan K, Smith SD. Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. J Dermatolog Treat. 2020;31(8):810-4. doi:10.1080/09546634.2020.1715895
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-48. doi:10.1056/NEJMoa1610020
Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459-73. doi:10.1111/bjd.17430
Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegräber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab—clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6(5):1778-80.e1. doi:10.1016/j.jaip.2018.03.020
Wollenberg A, Thomsen SF, Lacour JP, Jaumont X, Lazarewicz S. Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence. World Allergy Organ J. 2021;14(5):100519. doi:10.1016/j.waojou.2021.100519
Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847. doi:10.3389/fimmu.2019.02847
Reich K, Kabashima K, Peris K, et al. Efficacy and safety of Baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333-43. doi:10.1001/jamadermatol.2020.3628
Silverberg JI, Simpson EL, Wollenberg A, et al. Long-term efficacy of Baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials. JAMA Dermatol. 2021;157(6):691-9. doi:10.1001/jamadermatol.2021.0955
Silverberg JI, de Bruin-Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD UP study results. J Allergy Clin Immunol. 2022;149(3):977-87. doi:10.1016/j.jaci.2021.10.028
Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158(4):808-17. doi:10.1111/j.1365-2133.2007.08347.x
